Royalty Pharma plc (RPRX)
Automate Your Wheel Strategy on RPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including RPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RPRX
- Rev/Share 5.2237
- Book/Share 22.5834
- PB 2.1554
- Debt/Equity 1.1389
- CurrentRatio 1.5583
- ROIC 0.0956
- MktCap 18701775245.0
- FreeCF/Share 6.2301
- PFCF 6.9255
- PE 13.1977
- Debt/Assets 0.4326
- DivYield 0.0259
- ROE 0.1619
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RPRX | Morgan Stanley | -- | Overweight | -- | $51 | May 16, 2025 |
News
Royalty Pharma: Again, Guidance Raised, Buy Confirmed
Published: May 11, 2025 by: Seeking Alpha
Sentiment: Positive
Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche, with adjusted EBITDA reaching $738 million. The company raised its 2025 Portfolio Receipts guidance to $2.97-$3.12 billion, suggesting potential growth opportunities not yet reflected in the current valuation. RPRX repurchased 23 million shares for $723 million and has a $2.3 billion buyback remaining, with a 2.6% dividend yield.
Read More
Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Royalty Pharma plc (NASDAQ:RPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and CEO Marshall Urist - Executive Vice President and Head, Research and Investment Terry Coyne - Executive Vice President and CFO Chris Hite - Executive Vice President and Vice Chairman Conference Call Participants Hardik Parikh - JPMorgan Mike Nedelcovych - TD Cowen Terence Flynn - Morgan Stanley Geoff Meacham - Citi Jason Gerberry - Bank of America Securities Operator Ladies and gentlemen, thank you for standing …
Read More
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Royalty Pharma (RPRX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.98 per share a year ago.
Read More
Royalty Pharma Reports First Quarter 2025 Results
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.
Read More
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Read More
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Positive
Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend).
Read More
Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Royalty Pharma plc (NASDAQ:RPRX ) Q4 2024 Earnings Conference Call February 11, 2024 8:30 AM ET Company Participants George Grofik - SVP, Head, Investor Relations and Communications Pablo Legorreta - Founder & CEO Marshall Urist - EVP, Head-Research and Investments Christopher Hite - Vice Chairman & Executive VP Terrance Coyne - Executive VP & CFO Conference Call Participants Geoffrey Meacham - Citi Christopher Schott - JPMorgan Chase & Co Michael Nedelcovych - TD Cowen Chris Shibutani - Goldman Sachs Dina Ramadane - Bank of America Securities. Ashwani Verma - UBS Operator Ladies and gentlemen, thank you for standing by, and …
Read More
About Royalty Pharma plc (RPRX)
- IPO Date 2020-06-16
- Website https://www.royaltypharma.com
- Industry Biotechnology
- CEO Mr. Pablo Gerardo Legorreta
- Employees 75